Compare BridgeBio Pharma Inc (BBIO) vs CSX Corporation (CSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs CSX Corporation — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while CSX Corporation trades at $50 (market cap $92.24B). The key difference: CSX Corporation is far larger — about 5.6× BridgeBio Pharma Inc's market cap, and CSX Corporation pays a 1.13% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | CSX | |
|---|---|---|
Market Cap | $16.46B | $92.24B |
Sector | Health | Industrials |
52-Week High | $90.17 | $49.92 |
52-Week Low | $44.81 | $32.05 |
Enterprise Value | $18.02B | $110.47B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
CSX trades at $49.64, up 0.47% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed recent earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results expected soon. Revenue has trended down from $14.9B in 2022 to $14.1B in 2025, though net margins remain above 20%. Strong cash flow from operations supports dividends, including a recent $0.14 payout.
Outlook is cautiously optimistic given analyst consensus favoring Buy ratings (56.52%) and a price target near $48.87. Risks include declining revenue, high debt levels, and valuation multiples above industry norms. Earnings growth and operational efficiency gains are key catalysts for upside, but macroeconomic pressures on freight demand pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
